Long-Term Use of Omalizumab for Chronic Idiopathic Urticaria

Omalizumab is recommended for patients with moderate to severe chronic idiopathic urticaria (CIU) unresponsive to nonsedating H1 antihistamines. It is used long-term for CIU, but evidence beyond 24 weeks is limited.

This drug utilization study and systematic review aimed to determine real-world omalizumab use patterns in patients with CIU in 4 Canadian provinces, the efficacy and effectiveness of long-term use, and whether extended use is safe for patients.

Access the full study and associated resources:

Date Released: April 4, 2024

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.